• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Almac Group

    Syngene

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Alcami

    Syngene

    PCI Pharma Services

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    FDA & Data Integrity

    FDA Publishes Final Guidance on Data Integrity

    FDA & Data Integrity
    Related CONTENT
    • Mogene
    • Vetio Animal Health
    • Contracting And Outsourcing Exhibitor List
    • Do You Have Weaknesses? Of Course I Do!
    • FDA Approves MabPlex's IND
    Robert Marohn, Director of Quality Business Systems, Kite Pharmaceutical01.25.19
    On December 13, 2018 the U.S. Food and Drug Administration (FDA) released the final version of its guidance titled, “Data Integrity and Compliance with Drug CGMP: Questions and Answer.”1 The guidance is preceded by a statement released a day earlier from FDA Commissioner Scott Gottlieb, M.D., on “…the agency’s efforts to improve drug quality through data integrity and good manufacturing practice oversight.”2
    The guidance and statement place an exclamation point on FDA’s focus on “ensuring data associated with drug manufacturing are complete, consistent, and accurate, and therefore reliable,” as emphasized by Commissioner Gottlieb. This article looks at the important elements of FDA’s final data integrity guidance, its impact to contract pharmaceutical organizations, and notable updates from FDA’s draft version of the guidance.

    While FDA expects all data to be reliable and accurate, the introduction of the final guidance emphasizes that firms should “implement meaningful and effective strategies to manage their data integrity risks based on their process understanding and knowledge management of technologies and business models.” For more information on risk assessment and analysis, see Contract Pharma’s September 2017 feature, “Data Integrity: A Practical and Risk-Based Approach.”3

    Guidance Background
    Dr. Gottlieb noted, “Over the past decade, we’ve [FDA] uncovered situations in which drug quality data and information are not accurate.” Indeed, trends show an increase of data integrity sightings by the FDA since 2008. Recently, the number of data integrity associated Warning Letters have been dramatically increasing with 15 (0 U.S.) in 2015, 41 (7 U.S.) in 2016, 56 (19 U.S.) in 2017.4 Most often such data integrity observations result from inadequate processes and systems to ensure reliable and accurate data, which in all cases, FDA regards as a risk to patient safety.

    As in the draft guidance, the background section of the final guidance clearly states that requirements with respect to data integrity already exist in 21 CFR parts 211, 212; as well as 21 CFR part 11 and goes on to list each part as it relates to data integrity. The message is clear that expectations of data integrity have long existed in predicate rules, and therefore companies are assumed to meet such requirements when complying with respective rules today.

    New in the background section of the final guidance, FDA says when considering how to meet many regulatory requirements related to data integrity, it may be useful to ask a series of questions. Data integrity stewards in organizations will want to carefully consider these questions to ensure they meet data integrity requirements. 2018 Warning Letter violations show a continued trend of infringements involving data integrity during CGMP inspections. A review of causes for these warnings found examples of 2018 data integrity violations related to each of the seven questions FDA states companies should consider (see Table 1 below).

    Guidance Q&As
    The bulk of the final guidance covers 18 questions and answers about data integrity that highlight the most important ideas the agency expects firms to understand. The concepts cover the design, operation, and monitoring of systems and controls to maintain data integrity. It clarifies key terms, including the definition of data integrity and ALCOA,6 while placing an emphasis on all aspects of data governance throughout the data life cycle. The final guidance states, “System design and controls should simplify the detection of errors, omissions and aberrant results throughout the data’s life cycle.”

    All the Q&As in this final guidance should be reviewed by contract pharmaceutical organizations to ensure they are adopting these principals in their data integrity programs. However, some notable Q&As for the contract pharmaceutical industry to consider in this final guidance include the following:

    • In Q&A #7 on “Who should review audit trails?” the guidance states, “…all production and control records, which includes audit trails, must be reviewed and approved by the quality unit.” And contract pharmaceutical firms will want to pay attention to FDA’s recommendation to “use a quality system approach to implementing oversight and review of CGMP records.” Specifically, FDA footnoted its guidance on Quality Systems Approach to Pharmaceutical CGMP Regulations. And for information about auditing as it relates to contract facilities, it footnoted its guidance on Contract Manufacturing Arrangements for Drugs: Quality Agreements. Related, see Contract Pharma June 2018 column, “Putting Data Integrity in Quality Agreements.”7

    • In Q&A #13 on “Why has FDA cited use of actual samples during ‘system suitability’ or test, prep, or equilibration runs in warning letters?” the FDA addresses the issue of “testing into compliance.” Contract manufacturers will want to remember, FDA states using a strategy of repeated testing until a passing result is obtained, then disregarding the out of specification results without scientific justification is unscientific and unacceptable under CGMPs.8 In addition, data integrity best practices require the complete life cycle of CGMP data be preserved.

    • In Q&A #14 on “Is it acceptable to only save the final results from reprocessed laboratory chromatography?” FDA says no, and emphasizes the data integrity concept of completeness. Again, the complete life cycle of CGMP data must be protected and maintained. FDA expects that aborted or incomplete results must be captured in an audit trail and also investigated and justified.

    Notable Updates from FDA Draft Data Integrity Guidance
    The final guidance, for the most part, aligns with the draft guidance released in April 2016. However, there are four modifications that standout in the final guidance: management involvement, restrictive access controls, enhanced audit trail reviews, and handling of invalidated data.

    FDA adds to the final guidance emphasis on the role of management to create a quality culture in the organization. Management should ensure employees understand that data integrity is an organizational core value and be encouraged to identify and promptly report data integrity issues.

    In the draft guidance, the FDA recognized that some manufacturers may be too small to have independent security role assignments. The final guidance does not, and emphasizes the importance of separating responsibilities related to administration from record content production accounts.

    Also, the final guidance clarifies when audit trails should be reviewed based on frequency and/or risk. If the timing for data reviews is already explicitly stated in a CGMP regulation, the frequency of audit trail review should match this timing. However, where not called out, a risk based approach may be used, taking into account the critical nature of the data and its impact on product quality. The guidance provides examples that give direction on this topic.

    Finally, the draft guidance did not spell out that invalidated data must be evaluated by the quality unit pursuant to release. However, the final guidance is clear; such data is within the scope of the quality unit’s batch record review before release.

    Conclusion
    In 2018 the Medicines and Healthcare products Regulatory Agency (MHRA) (see, “New GXP Data Integrity Guidance Published by MHRA,” in the April 2018 edition of Contract Pharma9) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) also finalized their draft guidance on data integrity, rounding out a year when we saw all of these organizations, along with the FDA, settle their thinking on the topic. FDA Commissioner Gottlieb states, “As the industry has globalized, we’ve expanded our partnerships with our international regulatory counterparts.”

    Expect regulatory agencies to exchange information about quality and data integrity related violations observed in facilities around the world. Expect these agencies to work together to advance best practices to help pharmaceutical companies improve their compliance with data integrity regulations as a key step to ensure the safety, efficacy, and quality of drugs. 


     


    References
    1. www.fda.gov/downloads/drugs/guidances/ucm495891.pdf
    2. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628244.htm
    3. www.contractpharma.com/issues/2017-09-01/view_features/data-integrity-a-practical-and-risk-based-approach
    4. www.pharmaceuticalonline.com/doc/an-analysis-of-fda-warning-letters-on-data-integrity-0003
    5. www.fda.gov/ICECI/EnforcementActions/WarningLetters/2018/default.htm
    6. Complete, consistent, and accurate data should be attributable, legible,contemporaneously recorded, original or a true copy, and accurate (ALCOA).
    7. www.contractpharma.com/issues/2018-06-01/view_columns/putting-data-integrity-in-quality-agreements/45262
    8. www.fda.gov/downloads/drugs/guidances/ucm070287.pdf
    9. www.contractpharma.com/issues/2018-04-01/view_columns/new-gxp-data-integrity-guidance-published-by-mhra/49675



     
    Robert Marohn is the Director of Quality Business Systems at Kite Pharmaceutical, a Gilead company. He has worked in the life science industry for over twenty years. Previously, he served as the Chief Information Officer of Worldwide Clinical Trials for eight years. He holds a Master of Science in the Management of Technology from Georgia Institute of Technology and is currently pursuing a Ph.D. in Information Systems and Technology at Claremont Graduate University.
    Related Searches
    • Manufacturing
    • quality
    • it
    • 21 CFR Part 11
    Suggested For You
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    Contracting And Outsourcing Exhibitor List Contracting And Outsourcing Exhibitor List
    Do You Have Weaknesses? Of Course I Do! Do You Have Weaknesses? Of Course I Do!
    FDA Approves MabPlex FDA Approves MabPlex's IND
    Recro Pharma Amends IV Meloxicam License Agreement with Alkermes Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
    FDA Grants Mustang Bio ODD FDA Grants Mustang Bio ODD
    Serialization Implementation Serialization Implementation
     Dedicated to Excellence Dedicated to Excellence
    Pharma Future: Trends to Watch Pharma Future: Trends to Watch
    Anti-Cancer Evaluations with ICH S9 Guideline: What you need to know Anti-Cancer Evaluations with ICH S9 Guideline: What you need to know
    FDA Grants Albireo Pharma ODD FDA Grants Albireo Pharma ODD
    CPL Details Full-Service Offerings CPL Details Full-Service Offerings
    Reporting CPPs to FDA Reporting CPPs to FDA
    Renaissance Pharma at Contracting & Outsourcing 2018 Renaissance Pharma at Contracting & Outsourcing 2018

    Related Features

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20


    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Information Technology
      You Need Solutions, Digitization is the Answer

      You Need Solutions, Digitization is the Answer

      Cloud technology helps today’s contract manufacturers be agile, transparent and efficient.
      Brian Curran, Senior Vice President of Strategic Growth, MasterControl 10.14.20

    • Information Technology
      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

      The proven promise and huge potential of using AI and ML to accelerate drug discovery.
      Lucas Glass, Gary Shorter, and Rajneesh Patil, IQVIA 11.20.19


    • Information Technology
      A Brave New World of Data Integrity

      A Brave New World of Data Integrity

      How modern CMOs are keeping up with stringent regulatory guidelines by embracing advanced laboratory information systems.
      Bob Voelkner, VP Sales and Marketing, LabVantage 06.13.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19

    • Information Technology
      The Manufacturing Revolution In Medicine

      The Manufacturing Revolution In Medicine

      Real-time data insights help both pharma companies and contract manufacturers meet regulatory requirements while ensuring high production standards.
      Petter Moree, OSIsoft, LLC 05.07.19


    • Information Technology
      Industry 4.0 in the Pharma Industry

      Industry 4.0 in the Pharma Industry

      Digitization is not a single-handed project.
      Dr. Christian Hanisch, Project Manager Industry 4.0 Pharma, Bosch Packaging Technology 03.06.19

    • Information Technology
      Digitization: Pharma 4.0

      Digitization: Pharma 4.0

      A look at how technology is impacting the pharma industry
      Fatih Kaya and Gerald Buerkle, Vetter Pharma 01.25.19

    • Information Technology | Serialization | Supply Chain
      Serialization Compliance

      Serialization Compliance

      Automated data controls during packaging help improve compliance.
      Miguel Pitarch, Executive Director, Global Serialization, Bristol-Myers Squibb & the Bristol-Myers Squibb Serialization Team 11.13.18


    • Clinical Trial Materials | Information Technology
      Interactive Response Technology in Clinical Trial Supply

      Interactive Response Technology in Clinical Trial Supply

      Exploring the benefits of including IRT professionals earlier in trial planning
      Dave Holly, Senior Manager, IRT Development and Operations, Sharp Clinical Services 10.10.18

    • Drug Development | Information Technology | R&D
      CRO Industry Update: Big Data Drives Drug Development Efforts

      CRO Industry Update: Big Data Drives Drug Development Efforts

      With growth in virtual trials and RWE, the clinical development landscape may never look the same
      Kristin Brooks, Managing Editor 05.11.18

    • Information Technology | Serialization
      Stripping Serialization Back to Data Integrity

      Stripping Serialization Back to Data Integrity

      Why companies can’t afford to make compromises on quality
      Rachna Mohanka, Sr. Director, Global Solution Consulting, TraceLink 05.08.18

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login